Clinical and biological characteristics of the MDS cohort and relationship to TET2 mutations found at > 10% RMA
| Patient characteristics . | All n (%) . | TET2 mutated . | TET2 nonmutated . | P . |
|---|---|---|---|---|
| Number | 355 (100) | 55 (15.5) | 300 (84.5) | |
| Median age, y | 64.4 | 68.3 | 64.0 | < .01 |
| Range, y | (17.0-96.4) | (42.9-96.0) | (17.0-96.4) | |
| Sex, M/F | 214/141 | 34/21 | 180/120 | .06 |
| WHO classification | < .01 | |||
| RA/RCMD | 131 (36.9) | 17 (30.9) | 114 (38.0) | |
| RARS/RCMD-RS | 33 (9.3) | 6 (10.9) | 27 (9.0) | |
| RAEB-I/II | 105 (29.6) | 12 (21.8) | 93 (31.0) | |
| sAML | 35 (9.8) | 4 (7.3) | 31 (10.3) | |
| CMML-I/II | 35 (9.8) | 16 (29.1) | 19 (6.3) | |
| 5q- syndrome | 8 (2.3) | 0 (0) | 8 (2.7) | |
| MDS/MPN-U | 8 (2.3) | 0 (0) | 8 (2.7) | |
| Karyotype | .09 | |||
| Favorable | 192 (54.1) | 32 (58.2) | 160 (53.3) | |
| Intermediate | 60 (16.9) | 12 (21.9) | 48 (16.0) | |
| Poor | 71 (20.0) | 7 (12.7) | 64 (21.3) | |
| Missing | 32 (9.0) | 4 (7.2) | 28 (9.4) | |
| IPSS | .25 | |||
| Low/Int-1 | 192 (61.5) | 40 (72.7) | 152 (59.1) | |
| Int-2/High | 97 (31.1) | 13 (23.9) | 84 (32.7) | |
| Missing | 23 (7.4) | 2 (3.4) | 21 (8.2) | |
| Treatment | .08 | |||
| None/BSC | 211 (59.5) | 41 (74.6) | 170 (56.7) | |
| EPO/GCSF | 29 (8.2) | 1 (1.8) | 28 (9.3) | |
| 5-azacitidine | 14 (3.9) | 1 (1.8) | 13 (4.3) | |
| Intensive chemo ± transplant | 82 (23.1) | 11 (20.0) | 71 (23.7) | |
| Treatment data not available | 19 (5.3) | 1 (1.8) | 18 (6.0) |
| Patient characteristics . | All n (%) . | TET2 mutated . | TET2 nonmutated . | P . |
|---|---|---|---|---|
| Number | 355 (100) | 55 (15.5) | 300 (84.5) | |
| Median age, y | 64.4 | 68.3 | 64.0 | < .01 |
| Range, y | (17.0-96.4) | (42.9-96.0) | (17.0-96.4) | |
| Sex, M/F | 214/141 | 34/21 | 180/120 | .06 |
| WHO classification | < .01 | |||
| RA/RCMD | 131 (36.9) | 17 (30.9) | 114 (38.0) | |
| RARS/RCMD-RS | 33 (9.3) | 6 (10.9) | 27 (9.0) | |
| RAEB-I/II | 105 (29.6) | 12 (21.8) | 93 (31.0) | |
| sAML | 35 (9.8) | 4 (7.3) | 31 (10.3) | |
| CMML-I/II | 35 (9.8) | 16 (29.1) | 19 (6.3) | |
| 5q- syndrome | 8 (2.3) | 0 (0) | 8 (2.7) | |
| MDS/MPN-U | 8 (2.3) | 0 (0) | 8 (2.7) | |
| Karyotype | .09 | |||
| Favorable | 192 (54.1) | 32 (58.2) | 160 (53.3) | |
| Intermediate | 60 (16.9) | 12 (21.9) | 48 (16.0) | |
| Poor | 71 (20.0) | 7 (12.7) | 64 (21.3) | |
| Missing | 32 (9.0) | 4 (7.2) | 28 (9.4) | |
| IPSS | .25 | |||
| Low/Int-1 | 192 (61.5) | 40 (72.7) | 152 (59.1) | |
| Int-2/High | 97 (31.1) | 13 (23.9) | 84 (32.7) | |
| Missing | 23 (7.4) | 2 (3.4) | 21 (8.2) | |
| Treatment | .08 | |||
| None/BSC | 211 (59.5) | 41 (74.6) | 170 (56.7) | |
| EPO/GCSF | 29 (8.2) | 1 (1.8) | 28 (9.3) | |
| 5-azacitidine | 14 (3.9) | 1 (1.8) | 13 (4.3) | |
| Intensive chemo ± transplant | 82 (23.1) | 11 (20.0) | 71 (23.7) | |
| Treatment data not available | 19 (5.3) | 1 (1.8) | 18 (6.0) |